According to a new market report published by Lucintel, the future of the
API (chondroitin sulfate, hyaluronic acid, and pancreatin) market looks promising with opportunities in osteoarthritis, skin problems, exocrine pancreatic insufficiency, and ophthalmology applications. The global API (chondroitin sulfate, hyaluronic acid, and pancreatin) market is expected to grow with a CAGR of 7% from 2020 to 2025. The major drivers for this market are increasing prevalence of chronic diseases, such as osteoarthritis and gastric diseases, and rising clinical studies on different grade products used for treatment of different diseases.
To download report brochure, please go to https://www.lucintel.com/api-market.aspx and click "download brochure" tab from the menu
API (active pharmaceutical ingredient) is a substance or any combination of substance used in a pharmaceutical drug or pesticide that is biologically active. In this market, chondroitin sulfate, hyaluronic acid (natural and synthetic), and pancreatin are the major products. Lucintel forecasts that hyaluronic acid will remain the largest product segment over the forecast period due to rising prevalence of arthritis, increasing geriatric population, and development of advanced products containing hyaluronic acid visco-supplements.
Within this market, pharmaceutical companies will remain the largest end user segment over the forecast period due to rising number of clinical trials by pharmaceutical companies and growing regulatory compliance.
North America will remain the largest region over the forecast period due to increasing prevalence of osteoarthritis and presence of major companies for supplements and clinical trials in the region.
Summit Nutritionals International, Sioux Pharm, TSI Group, Shandong Runxin Biotechnology, ZPD, Pacific Rainbow International, Seikagaku, Synutra, Bioiberica, and Newgen Biotech are among the major suppliers in the global API (chondroitin sulfate, hyaluronic acid, and pancreatin) market.
Lucintel, a leading global strategic consulting and
market research firm, has analyzed growth opportunities in the global API (chondroitin sulfate, hyaluronic acid, and pancreatin) market by product, product form, end user, and region. Lucintel has prepared a comprehensive research report titled “
Growth Opportunities in the Global API (Chondroitin Sulfate, Hyaluronic Acid, and Pancreatin) Market 2020-2025: Trends, Forecast, and Opportunity Analysis.” This Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global API (chondroitin sulfate, hyaluronic acid, and pancreatin) market by product, product form, end user, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
-
Chondroitin Sulfate
-
Hyaluronic Acid
-
Pancreatin
By Product Form [Value ($ Million) shipment analysis for 2014 – 2025]:
-
Pellet Form
-
Powdered Form
-
Others
By End User [Value ($ Million) shipment analysis for 2014 – 2025]:
-
Pharmaceutical Companies
-
Biotechnology Companies
-
Others
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
-
United States
-
Canada
-
Mexico
-
United Kingdom
-
Germany
-
France
This more than 150 page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or visit us at helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision makers in a variety of industries. For further information, visit www.lucintel.com.
